Article tools
Author information
Published in Volume 100, Issue 12 (December 15,1997)
J. Clin. Invest. 100(12): 3027-3035 (1997). doi:10.1172/JCI119857.
Copyright © 1997, The American Society for Clinical Investigation

Research Article

Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences.

P I Karachunski, N S Ostlie, D K Okita and B M Conti-Fine

Department of Biochemistry, College of Biological Sciences, University of Minnesota, St. Paul, Minnesota 55108, USA.

Published December 15, 1997

T cell tolerization prevents and improves T cell-mediated experimental autoimmune diseases. We investigated here whether similar approaches could be used for antibody (Ab)-mediated autoimmune diseases. Myasthenia gravis, caused by IgG Ab against muscle acetylcholine receptor (AChR), is perhaps the best characterized of them. We used an animal model, experimental myasthenia gravis induced in C57Bl/6 mice by immunization with Torpedo acetylcholine receptor (TAChR), to demonstrate that nasal administration of synthetic sequences of the TAChR alpha-subunit- forming epitopes recognized by anti-TAChR CD4+ T helper cells (residues alpha150-169, alpha181-200, and alpha360-378), given before and during immunization with TAChR, causes decreased CD4+ responsiveness to those epitopes and to TAChR, reduced synthesis of anti-TAChR Ab, and prevented experimental myasthenia gravis. These effects were not induced by nasal administration of synthetic epitopes of diphtheria toxin. Secretion of IL-2, IL-4, and IL-10 by spleen T cells from TAChR immunized mice, in response to challenge with TAChR in vitro, indicated that in sham-tolerized mice only Th1 cells responded to TAChR, while peptide-treated mice had also an AChR-specific Th2 response. The TAChR peptide treatment induced also in vitro anergy to the TAChR of the spleen T cells, which was reversed by IL-2.

This article Copyright © 1997, The American Society for Clinical Investigation.

Articles that cite this article:

Vaccines against myasthenia gravis
Sonia Berrih-aknin, Sara Fuchs, Miriam C Souroujon
ebot 5(7):983. doi:10.1517/14712598.5.7.983 [CrossRef]

Nasal Administration of Synthetic Acetylcholine Receptor T Epitopes Affects the Immune Response to the Acetylcholine Receptor and Prevents Experimental Myasthenia Gravisa
PETER I. Karachunski, NORMA S. Ostlie, DAVID K. Okita, BIANCA M. Conti-fine
Ann N Y Acad Sci 841(1 myasthenia gr):560. doi:10.1111/j.1749-6632.1998.tb10983.x [CrossRef]

Mapping myasthenia gravis–associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice
Huan Yang, Elzbieta Goluszko, Chella David, David K. Okita, Bianca Conti-fine, Teh-sheng Chan, Mathilde A. Poussin, Premkumar Christadoss
J Clin Invest 109(8):1111. doi:10.1172/JCI14255 [CrossRef]

Heat-shock protein T-cell epitopes trigger a spreading regulatory control in a diversified arthritogenic T-cell response
Willem Eden, Ruurd Zee, Leonie S. Taams, A. Berent J. Prakken, Joel Roon, Marca H. M. Wauben
Immunol Rev 164(1):169. doi:10.1111/j.1600-065X.1998.tb01218.x [CrossRef]

Immune response of the coeliac nasal mucosa to locally-instilled gliadin
P. Torre, S. Fusco, F. Quaglia, M. L. LA Rotonda, F. Paparo, M. Maglio, R. Troncone, L. Greco
Clin Exp Immunol 127(3):513. doi:10.1046/j.1365-2249.2002.01760.x [CrossRef]

Acetylcholine receptors and myasthenia
Jon M. Lindstrom
Muscle Nerve 23(4):453. doi:10.1002/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O [CrossRef]

Amphipathic variable region heavy chain peptides derived from monoclonal human Wegener's anti-PR3 antibodies stimulate lymphocytes from patients with Wegener's granulomatosis and microscopic polyangiitis
E. Peen, C. Malone, C. Myers, R. C. Williams jr, A. B. Peck, E. Csernok, W. L. Gross, R. Staud
Clin Exp Immunol 125(2):323. doi:10.1046/j.1365-2249.2001.01482.x [CrossRef]

Reduction of human anti-tetanus toxoid antibody in hu-PBL-SCID mice by immunodominant peptides of tetanus toxoid
D. J. Jackson, C. J. Elson, B. M. Kumpel
Clin Exp Immunol 137(2):245. doi:10.1111/j.1365-2249.2004.02521.x [CrossRef]

Peptide-based therapeutic vaccines for allergic and autoimmune diseases
Mark Larché, David C Wraith
Nat Med 11(4s):S69. doi:10.1038/nm1226 [CrossRef]

Reactivity of T cells from women with antibodies to the human platelet antigen (HPA)-1a to peptides encompassing the HPA-1 polymorphism
D. J. Jackson, M. F. Murphy, P. W. Soothill, G. F. Lucas, C. J. Elson, B. M. Kumpel
Clin Exp Immunol 142(1):92. doi:10.1111/j.1365-2249.2005.02903.x [CrossRef]

Peptide-based immunotherapy: a novel strategy for allergic disease
F Runa Ali, Mark Larche
Expert Rev Vaccines 4(6):881. doi:10.1586/14760584.4.6.881 [CrossRef]

Characterization of the alloreactive helper T-cell response to the platelet membrane glycoprotein IIIa (integrin-beta3) in human platelet antigen-1a alloimmunized human platelet antigen-1b1b women
Hosea Sukati, Hagop Bessos, Robert N. Barker, Stanislaw J. Urbaniak
Transfusion (Malden) 45(7):1165. doi:10.1111/j.1537-2995.2005.00188.x [CrossRef]

Myasthenia gravis: past, present, and future
Bianca M. Conti-fine, Monica Milani, Henry J. Kaminski
J Clin Invest 116(11):2843. doi:10.1172/JCI29894 [CrossRef]

Coaxing the liver into preventing autoimmune disease in the brain
Brad E. Hoffman, Roland W. Herzog
J Clin Invest doi:10.1172/JCI37079 [CrossRef]